4142:TPE
Adimmune Corp
16,80 TWD
arrow_upward
+0,60%(+0,100) 1 pv
13.11., 13.30.11 UTC+8 · TWD
search
Kaikki symbolit
| Symboli | Hinta | Muutos | Muutos (%) |
|---|
insights_autoLuodaan huippuvinkkejä: 4142…
Avaa
16,85 TWD
Korkea
17,15 TWD
Matala
16,75 TWD
Markkina-arvo
7,22 mrd.
Keskimääräinen volyymi
1,13 milj.
Volyymi
724,64 t.
52 viikon ylin
22,50 TWD
52 viikon alin
15,65 TWD
Osakekohtainen tulos (EPS)
−0,34 TWD
Liikkeellä olevat osakkeet
235,29 milj.
Työntekijöiden lukumäärä
564
Avaa
16,85 TWD
Korkea
17,15 TWD
Matala
16,75 TWD
Markkina-arvo
7,22 mrd.
Keskimääräinen volyymi
1,13 milj.
Volyymi
724,64 t.
52 viikon ylin
22,50 TWD
52 viikon alin
15,65 TWD
Osakekohtainen tulos (EPS)
−0,34 TWD
Liikkeellä olevat osakkeet
235,29 milj.
Työntekijöiden lukumäärä
564
Uutiset
Verkkolähteistä ja uutiskumppaneilta
The Motley Fool
·
48 minuuttia sitten
History Says Every S&P 500 Bear Market Has Ended the Same Way. Here's the Pattern.
TradingKey
·
9 tuntia sitten
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
TradingView
·
16 tuntia sitten
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Traders Union
·
1 tunti sitten
Quinten Francois: Bitcoin and Ethereum underperform S&P 500 over five years
Profiili
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Tietoa: Adimmune Corp
Toimitusjohtaja-
Työntekijät564
Perustamispäivä1965
Päätoimipaikka-
ToimialaHealth Care
Toimiala-
Sivustoadimmune.com.tw